Michelle Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michelle Wilson has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Graeme Coulson
ASchool of BioSciences, The University of Melbourne, Gate 13, Royal Parade, Parkville, Melbourne, Vic. 3010, Australia
2 shared publications- Graeme Coulson
ASchool of BioSciences, The University of Melbourne, Vic 3010, Australia
2 shared publications - Rory Wolfe
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
2 shared publications Ann G. Russell
Division of Physical Therapy, Walsh University, North Canton, OH, USA
1 shared publication- Annette Jane Dobson
School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia
1 shared publication - Catherine A. Herbert
School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 30 (3) , 177-184
Effect of Aspirin on Development of First and Recurrent Primary Cutaneous Keratinocyte Carcinomas in Older Australian Adults: Extended Follow-up of a Large Randomised Controlled Trial
Emma Hiscutt, Mabel Yan, Victoria Mar, Rory Wolfe, Ruth Trevaks, Michelle Wilson, Suzanne Gaye Orchard. J Cancer Prev 2025;30:177-84. https://doi.org/10.15430/JCP.25.017
- 30 September 2025
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 30 (3) , 177-184
Open AccessEffect of Aspirin on Development of First and Recurrent Primary Cutaneous Keratinocyte Carcinomas in Older Australian Adults: Extended Follow-up of a Large Randomised Controlled Trial
Emma Hiscutt, Mabel Yan, Victoria Mar, Rory Wolfe, Ruth Trevaks, Michelle Wilson, Suzanne Gaye Orchard. J Cancer Prev 2025;30:177-84. https://doi.org/10.15430/JCP.25.017
- 1 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (2) , 671-681
Validation of multiple linked administrative datasets to identify people with dementia
Background: Accurately measuring dementia prevalence and incidence (including Alzheimer's disease) is important for service planning and chronic condition management. Linked administrative data present an accessible and inexpensive method to estimate dementia prevalence and incidence. Objective: To examine the accuracy of identifying people with dementia in linked administrative data through comparison with adjudicated cases of dementia from a community-based clinical trial. Methods: We created a comprehensive linked administrative dataset containing people with dementia in Australia and used it to develop algorithms that identified people with dementia. These algorithms were tested against adjudicated cases of dementia (both confirmed and not confirmed) in the ASPirin in Reducing Events in the Elderly (ASPREE) clinical trial (Number: ISRCTN83772183, Registration date: 14/07/2005) to help determine optimal sensitivity and specificity. Results: The algorithm that provided the highest sensitivity and positive predictive value estimates on balance without excluding ASPREE trial participants with suspected (but not confirmed) dementia was having at least one record for dementia in a minimum of two sources or two records with dementia in one source based on truncating the timeframe of randomization in the ASPREE trial to one year from the date that the first participant was randomized. This algorithm produced a sensitivity of 70.7%, specificity of 98.2%, positive predictive value of 72.6% and negative predictive value of 98.1%. Conclusions: Linked administrative data can identify people with dementia with moderate accuracy. This is promising but requires enhancement before it can be used for estimating dementia prevalence and incidence. Clinical trial name and URL: ASPirin in Reducing Events in the Elderly; ISRCTN - ISRCTN83772183: ASPirin in Reducing Events in the Elderly ( https://www.isrctn.com/ISRCTN83772183 )
- 1 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (2) , 671-681
Validation of multiple linked administrative datasets to identify people with dementia
Background: Accurately measuring dementia prevalence and incidence (including Alzheimer's disease) is important for service planning and chronic condition management. Linked administrative data present an accessible and inexpensive method to estimate dementia prevalence and incidence. Objective: To examine the accuracy of identifying people with dementia in linked administrative data through comparison with adjudicated cases of dementia from a community-based clinical trial. Methods: We created a comprehensive linked administrative dataset containing people with dementia in Australia and used it to develop algorithms that identified people with dementia. These algorithms were tested against adjudicated cases of dementia (both confirmed and not confirmed) in the ASPirin in Reducing Events in the Elderly (ASPREE) clinical trial (Number: ISRCTN83772183, Registration date: 14/07/2005) to help determine optimal sensitivity and specificity. Results: The algorithm that provided the highest sensitivity and positive predictive value estimates on balance without excluding ASPREE trial participants with suspected (but not confirmed) dementia was having at least one record for dementia in a minimum of two sources or two records with dementia in one source based on truncating the timeframe of randomization in the ASPREE trial to one year from the date that the first participant was randomized. This algorithm produced a sensitivity of 70.7%, specificity of 98.2%, positive predictive value of 72.6% and negative predictive value of 98.1%. Conclusions: Linked administrative data can identify people with dementia with moderate accuracy. This is promising but requires enhancement before it can be used for estimating dementia prevalence and incidence. Clinical trial name and URL: ASPirin in Reducing Events in the Elderly; ISRCTN - ISRCTN83772183: ASPirin in Reducing Events in the Elderly ( https://www.isrctn.com/ISRCTN83772183 )
- Open Access
- 2 November 2021
- Published by Wiley in Ecological Management & Restoration
- Vol. 22 (S1) , 157-166
Early warning signs of population irruptions in Eastern Grey Kangaroo (Macropus giganteus)
- 2 November 2021
- Published by Wiley in Ecological Management & Restoration
- Vol. 22 (S1) , 157-166
Open AccessEarly warning signs of population irruptions in Eastern Grey Kangaroo (Macropus giganteus)
- Open Access
- 2 November 2021
- Published by Wiley in Ecological Management & Restoration
- Vol. 22 (S1) , 147-156
Fertility control for managing macropods – Current approaches and future prospects
Summary: Macropods play an important ecological role in the Australian environment; however, at high population densities can adversely affect biodiversity and primary production and result in human–wildlife conflicts. While shooting is recognised as the most humane and species‐specific method for controlling macropod populations, in peri‐urban situations fertility control provides an attractive option to replace or reduce lethal interventions. An appropriate fertility control agent for managing overabundant macropods needs to provide long‐lasting infertility following a single treatment, be species‐specific in its action or administration method, and be safe, humane, and cost‐effective. Several contraceptive methods that induce infertility for multiple years have been tested on macropods. These include surgical techniques; hormonal implants containing deslorelin, a gonadotrophin‐releasing hormone (GnRH) agonist, or levonorgestrel, a progestin; and immunocontraceptive vaccines (zona pellucida vaccine and the GnRH‐based vaccine, GonaCon). These methods vary in the complexity of delivery and therefore their potential for adverse welfare impacts. Minimal side effects on behaviour and health have been observed. Despite some recent progress with remote dart delivery of deslorelin implants and GonaCon, efficient deployment of all existing methods is currently restricted to either captive or small, wild populations where individuals can be approached closely enough for safe capture and treatment. Of the currently available methods, levonorgestrel and GonaCon are the most suited to population‐scale management. To date, studies addressing the effect of fertility control on the growth rate of macropod populations have been limited but are essential to enable full evaluation of the efficacy and cost/benefit analysis of the different approaches. Mathematical modelling to identify the level of infertility required to meet population management goals, as well as comparing integrated management strategies, will support planning of large‐scale field trials. Improving dart delivery of existing contraceptive agents and developing new methods, such as an oral contraceptive, would increase the cost‐effectiveness of applying fertility control to free‐ranging macropods and may make treating larger populations feasible.
- 2 November 2021
- Published by Wiley in Ecological Management & Restoration
- Vol. 22 (S1) , 147-156
Open AccessFertility control for managing macropods – Current approaches and future prospects
Summary: Macropods play an important ecological role in the Australian environment; however, at high population densities can adversely affect biodiversity and primary production and result in human–wildlife conflicts. While shooting is recognised as the most humane and species‐specific method for controlling macropod populations, in peri‐urban situations fertility control provides an attractive option to replace or reduce lethal interventions. An appropriate fertility control agent for managing overabundant macropods needs to provide long‐lasting infertility following a single treatment, be species‐specific in its action or administration method, and be safe, humane, and cost‐effective. Several contraceptive methods that induce infertility for multiple years have been tested on macropods. These include surgical techniques; hormonal implants containing deslorelin, a gonadotrophin‐releasing hormone (GnRH) agonist, or levonorgestrel, a progestin; and immunocontraceptive vaccines (zona pellucida vaccine and the GnRH‐based vaccine, GonaCon). These methods vary in the complexity of delivery and therefore their potential for adverse welfare impacts. Minimal side effects on behaviour and health have been observed. Despite some recent progress with remote dart delivery of deslorelin implants and GonaCon, efficient deployment of all existing methods is currently restricted to either captive or small, wild populations where individuals can be approached closely enough for safe capture and treatment. Of the currently available methods, levonorgestrel and GonaCon are the most suited to population‐scale management. To date, studies addressing the effect of fertility control on the growth rate of macropod populations have been limited but are essential to enable full evaluation of the efficacy and cost/benefit analysis of the different approaches. Mathematical modelling to identify the level of infertility required to meet population management goals, as well as comparing integrated management strategies, will support planning of large‐scale field trials. Improving dart delivery of existing contraceptive agents and developing new methods, such as an oral contraceptive, would increase the cost‐effectiveness of applying fertility control to free‐ranging macropods and may make treating larger populations feasible.
- 12 May 2016
- Published by CSIRO Publishing in Wildlife Research
- Vol. 43 (3) , 212-219
Comparative efficacy of levonorgestrel and deslorelin contraceptive implants in free-ranging eastern grey kangaroos (Macropus giganteus)
Context: Fertility control of females with levonorgestrel or deslorelin implants shows promise for managing populations of overabundant eastern grey kangaroos (Macropus giganteus). Although these implants have been tested separately in captive and free-ranging kangaroos, there has been no direct comparison under equivalent field conditions. Aims: We investigated the long-term efficacy of levonorgestrel and deslorelin implants, together with the cost of treatment, ease of administration, and the welfare of the animals, in a side-by-side trial under realistic management conditions. Methods: We captured 65 adult female kangaroos over 11 days at a golf course in Anglesea, Victoria, Australia. We assigned each female to one of the following three experimental groups: levonorgestrel (210 mg, n = 18), deslorelin (9.4 mg, n = 24) or procedural control (n = 23). We monitored reproductive success for 8 years, by observing young in the pouch in winter and spring. Key results: Natural fertility was high; in most years, less than 20% of control females failed to reproduce. For deslorelin-treated females, the odds of failing to reproduce were four times higher than for the control group; for levonorgestrel-treated females, these odds were 74 times higher. Deslorelin was ineffective after 3 years, whereas levonorgestrel was effective for at least 5 years. Conclusions: Levonorgestrel was markedly superior in efficacy, as shown by a stronger contraceptive effect persisting for longer. In other respects, the two implants were comparable, being similar in cost and ease of delivery, and equally safe. Implications: Only levonorgestrel implants fulfill their promise for non-lethal, long-term control of kangaroo populations. Deslorelin implants cannot be recommended for this purpose.
- 12 May 2016
- Published by CSIRO Publishing in Wildlife Research
- Vol. 43 (3) , 212-219
Comparative efficacy of levonorgestrel and deslorelin contraceptive implants in free-ranging eastern grey kangaroos (Macropus giganteus)
Context: Fertility control of females with levonorgestrel or deslorelin implants shows promise for managing populations of overabundant eastern grey kangaroos (Macropus giganteus). Although these implants have been tested separately in captive and free-ranging kangaroos, there has been no direct comparison under equivalent field conditions. Aims: We investigated the long-term efficacy of levonorgestrel and deslorelin implants, together with the cost of treatment, ease of administration, and the welfare of the animals, in a side-by-side trial under realistic management conditions. Methods: We captured 65 adult female kangaroos over 11 days at a golf course in Anglesea, Victoria, Australia. We assigned each female to one of the following three experimental groups: levonorgestrel (210 mg, n = 18), deslorelin (9.4 mg, n = 24) or procedural control (n = 23). We monitored reproductive success for 8 years, by observing young in the pouch in winter and spring. Key results: Natural fertility was high; in most years, less than 20% of control females failed to reproduce. For deslorelin-treated females, the odds of failing to reproduce were four times higher than for the control group; for levonorgestrel-treated females, these odds were 74 times higher. Deslorelin was ineffective after 3 years, whereas levonorgestrel was effective for at least 5 years. Conclusions: Levonorgestrel was markedly superior in efficacy, as shown by a stronger contraceptive effect persisting for longer. In other respects, the two implants were comparable, being similar in cost and ease of delivery, and equally safe. Implications: Only levonorgestrel implants fulfill their promise for non-lethal, long-term control of kangaroo populations. Deslorelin implants cannot be recommended for this purpose.
- 23 August 2013
- Published by CSIRO Publishing in Wildlife Research
- Vol. 40 (5) , 403-412
Deslorelin implants in free-ranging female eastern grey kangaroos (Macropus giganteus): mechanism of action and contraceptive efficacy
Context: Fertility control offers a non-lethal management technique for iconic yet overabundant wildlife. Slow-release hormonal implants containing deslorelin show promise for managing free-ranging populations, particularly in peri-urban reserves, but most studies have been limited to captivity. Aims: We investigated the efficacy and mechanism of deslorelin implants in free-ranging female eastern grey kangaroos (Macropus giganteus) under realistic management conditions. Methods: We assigned females to a deslorelin (9.4 mg, n = 53) or placebo (n = 56) group at three peri-urban sites in Victoria, Australia, and monitored reproductive success for 3 years by observing young in the pouch. We tested the plasma LH response of control and treated females to exogenous GnRH, and compared the size of ovarian follicles between the two groups. Key results: Deslorelin implants reduced fertility at all three sites. No deslorelin-treated females bred in Year 1 at Anglesea and Serendip versus 42% and 44% of control females respectively. At Plenty Gorge, 60% of deslorelin-treated females bred in Year 1 versus 100% of control females. In Year 2, between 11% and 39% of the treated females bred versus between 82% and 100% of control females at all sites. The contraceptive efficacy reduced by Year 3 when between 43% and 57% of the treated females bred versus between 85% and 100% of controls. A GnRH challenge elicited higher plasma LH concentrations in control than in treated females, and unlike untreated females, treated females lacked ovarian follicles >2 mm. Conclusions: Deslorelin implants reduced fertility in free-ranging female eastern grey kangaroos over three successive breeding seasons. Chronic exposure to deslorelin desensitised the pituitary gland to GnRH and suppressed follicular development, but did not inhibit the development of a blastocyst, pregnancy or lactation in at least some females that had conceived before treatment. Implications: Effective population management using deslorelin implants will require females to be re-treated on multiple occasions because the contraceptive effect lasts only a portion of their reproductive life. This would be practical only at sites where kangaroos are relatively easy to capture. The timing of treatment is also important in a species that undergoes embryonic diapause, particularly at sites providing high-quality habitat.
- 23 August 2013
- Published by CSIRO Publishing in Wildlife Research
- Vol. 40 (5) , 403-412
Deslorelin implants in free-ranging female eastern grey kangaroos (Macropus giganteus): mechanism of action and contraceptive efficacy
Context: Fertility control offers a non-lethal management technique for iconic yet overabundant wildlife. Slow-release hormonal implants containing deslorelin show promise for managing free-ranging populations, particularly in peri-urban reserves, but most studies have been limited to captivity. Aims: We investigated the efficacy and mechanism of deslorelin implants in free-ranging female eastern grey kangaroos (Macropus giganteus) under realistic management conditions. Methods: We assigned females to a deslorelin (9.4 mg, n = 53) or placebo (n = 56) group at three peri-urban sites in Victoria, Australia, and monitored reproductive success for 3 years by observing young in the pouch. We tested the plasma LH response of control and treated females to exogenous GnRH, and compared the size of ovarian follicles between the two groups. Key results: Deslorelin implants reduced fertility at all three sites. No deslorelin-treated females bred in Year 1 at Anglesea and Serendip versus 42% and 44% of control females respectively. At Plenty Gorge, 60% of deslorelin-treated females bred in Year 1 versus 100% of control females. In Year 2, between 11% and 39% of the treated females bred versus between 82% and 100% of control females at all sites. The contraceptive efficacy reduced by Year 3 when between 43% and 57% of the treated females bred versus between 85% and 100% of controls. A GnRH challenge elicited higher plasma LH concentrations in control than in treated females, and unlike untreated females, treated females lacked ovarian follicles >2 mm. Conclusions: Deslorelin implants reduced fertility in free-ranging female eastern grey kangaroos over three successive breeding seasons. Chronic exposure to deslorelin desensitised the pituitary gland to GnRH and suppressed follicular development, but did not inhibit the development of a blastocyst, pregnancy or lactation in at least some females that had conceived before treatment. Implications: Effective population management using deslorelin implants will require females to be re-treated on multiple occasions because the contraceptive effect lasts only a portion of their reproductive life. This would be practical only at sites where kangaroos are relatively easy to capture. The timing of treatment is also important in a species that undergoes embryonic diapause, particularly at sites providing high-quality habitat.